Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 10, 2007 at 6:01 PM

MediQuest Therapeutics Prepares To Seek FDA’s Nod

Pharmaceutical start-up MediQuest Therapeutics, which specializes on topical treatments, is getting ready to seek regulatory approval of its first commercial treatment.

In late June, the privately held Bothell firm concluded its final clinical study of a therapy to treat Raynaud’s disease, a disorder that makes the body’s extremities overreact to cold temperatures.

MediQuest expects to file an application for the new treatment with the U.S. Food and Drug Administration “sometime before the end of the year,” says Chief Executive Frederick Dechow. A new round of financing to underwrite the company’s effort lies in the “not too distant future,” he added.

The market for Raynaud’s disease treaments could be in excess of $800 million a year, Dechow said. A successful venture round — and product launch — could mean up to 100 additional jobs, Dechow said. The company currently has 28 employees.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►